Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression.
暂无分享,去创建一个
R. Sherwin | F. Markland | Gary Fujii | Dongyun Yang | G. Fujii | W. Ernst | Stephen Swenson | Fritz Costa | Radu Minea | Russell P Sherwin | William Ernst | Francis S Markland | Dongyun Yang | Fritz K. Costa | S. Swenson | R. Minea
[1] R. Bau,et al. Purification, crystallization and preliminary X-ray analysis of the disintegrin contortrostatin from Agkistrodon contortrix contortrix snake venom. , 2002, Acta crystallographica. Section D, Biological crystallography.
[2] G. Fujii. LIPOSOMAL AMPHOTERICIN B (AMBISOME) : REALIZATION OF THE DRUG DELIVERY CONCEPT , 1996 .
[3] P. Newman,et al. The Role of PECAM‐1 in Vascular Cell Biology a , 1994, Annals of the New York Academy of Sciences.
[4] David A. Cheresh,et al. Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.
[5] F. Markland,et al. Contortrostatin activates ERK2 and tyrosine phosphorylation events via distinct pathways. , 2000, Biochemical and biophysical research communications.
[6] Raghu Kalluri,et al. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[7] M. Kieran,et al. Antiangiogenesis therapy. Current and future agents. , 2001, Hematology/oncology clinics of North America.
[8] Y. Jang,et al. Inhibitory effect of the salmosin gene transferred by cationic liposomes on the progression of B16BL6 tumors. , 2003, Cancer research.
[9] R. Klemke,et al. Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo. , 1997, The Journal of clinical investigation.
[10] F. Sarkar,et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. , 1995, The Journal of clinical investigation.
[11] D. Cheresh,et al. Integrins and cancer. , 1996, Current opinion in cell biology.
[12] J. Price,et al. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. , 1990, Cancer research.
[13] K. Yagi,et al. Effect of adriamycin entrapped by sulfatide-containing liposomes on ovarian tumor-bearing nude mice. , 1986, Biotechnology and applied biochemistry.
[14] R. Langer,et al. Drug delivery and targeting. , 1998, Nature.
[15] P. Brooks,et al. Role of integrins in angiogenesis. , 1996, European journal of cancer.
[16] F. Markland,et al. Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin. , 2001, Toxicon : official journal of the International Society on Toxinology.
[17] R K Jain,et al. Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.
[18] M. Woodle. Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation. , 1993, Chemistry and physics of lipids.
[19] E. Ruoslahti. Specialization of tumour vasculature , 2002, Nature Reviews Cancer.
[20] E. Winer,et al. Liposomal anthracyclines for breast cancer. , 2001, Seminars in oncology.
[21] T. Coley,et al. The formation of amphotericin B ion channels in lipid bilayers. , 1997, Biochemistry.
[22] A. Kidera,et al. Tailoring echistatin to possess higher affinity for integrin alpha(IIb)beta(3). , 1996, FEBS Letters.
[23] H. Dvorak,et al. Leaky tumor vessels: consequences for tumor stroma generation and for solid tumor therapy. , 1990, Progress in clinical and biological research.
[24] C. Shapiro,et al. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Calvete,et al. Importance of the structure of the RGD-containing loop in the disintegrins echistatin and eristostatin for recognition of alpha IIb beta 3 and alpha v beta 3 integrins. , 1996, FEBS Letters.
[26] J. Folkman,et al. The role of angiogenesis in tumor growth. , 1992, Seminars in cancer biology.
[27] S. Groshen,et al. Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits breast cancer progression. , 2000, Breast cancer research and treatment.
[28] P. K. Smith,et al. Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.
[29] K. Meerovitch,et al. A novel RGD antagonist that targets both αvβ3 and α5β1 induces apoptosis of angiogenic endothelial cells on type I collagen , 2003 .
[30] C. Garlanda,et al. Involvement of endothelial PECAM-1/CD31 in angiogenesis. , 1997, The American journal of pathology.
[31] R. Pardi,et al. The platelet endothelial cell adhesion molecule‐1 (PECAM1) contributes to endothelial barrier function , 1995, FEBS letters.
[32] N. Weidner,et al. Intratumoral microvessel density and L53 protein: Correlation with metastasis in head‐and‐neck squamous‐cell carcinoma , 1993, International journal of cancer.
[33] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[34] C. Osborne,et al. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. , 1985, Cancer research.
[35] D. S. Kim,et al. A novel disintegrin salmosin inhibits tumor angiogenesis. , 1999, Cancer research.
[36] R. Jain. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. , 2002, Seminars in oncology.
[37] F. Greenwood,et al. Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity , 1962, Nature.
[38] F. Kabbinavar,et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] C. Teng,et al. Triflavin, an RGD-containing antiplatelet peptide, binds to GpIIIa of ADP-stimulated platelets. , 1992, Biochemical and biophysical research communications.
[40] F. Greenwood,et al. THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. , 1963, The Biochemical journal.
[41] M. Trikha,et al. Purification and characterization of platelet aggregation inhibitors from snake venoms. , 1994, Thrombosis research.
[42] D. Cheresh,et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. , 1994, Cell.
[43] H. Dvorak,et al. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. , 1988, The American journal of pathology.
[44] L. Romer,et al. EndoCAM: a novel endothelial cell-cell adhesion molecule , 1990, The Journal of cell biology.
[45] U. K. Laemmli,et al. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.
[46] M. Gobbi,et al. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia , 2002, Annals of Hematology.
[47] L. Ellis,et al. Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin™) to chemotherapy improves survival in metastatic colorectal cancer , 2003 .
[48] F. Markland,et al. Contortrostatin, a snake venom disintegrin, induces αvβ3‐mediated tyrosine phosphorylation of CAS and FAK in tumor cells , 2000 .
[49] S. Terada,et al. Ussuristatin 2, a novel KGD-bearing disintegrin from Agkistrodon ussuriensis venom. , 1999, Journal of biochemistry.
[50] M. Trikha,et al. Contortrostatin, a snake venom disintegrin, inhibits beta 1 integrin-mediated human metastatic melanoma cell adhesion and blocks experimental metastasis. , 1994, Cancer research.
[51] P. Brooks,et al. Contortrostatin, a Homodimeric Disintegrin, Binds to Integrin αvβ5 , 2000 .
[52] C. Yeh,et al. A new short chain RGD-containing disintegrin, accutin, inhibits the common pathway of human platelet aggregation. , 1998, Biochimica et biophysica acta.
[53] D. Cheresh,et al. Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.
[54] R. Kerbel,et al. Antiangiogenic scheduling of lower dose cancer chemotherapy. , 2001, Cancer journal.
[55] A. Giaccia,et al. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.
[56] Athens Greece,et al. Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[57] F. Giancotti,et al. Integrin-mediated adhesion and signaling in tumorigenesis. , 1994, Biochimica et biophysica acta.
[58] L. Ellis,et al. Inhibition of integrin α5β1 function with a small peptide (ATN‐161) plus continuous 5‐FU infusion reduces colorectal liver metastases and improves survival in mice , 2003, International journal of cancer.
[59] J. Gorski,et al. PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. , 1990, Science.
[60] J. Marx. A Boost for Tumor Starvation , 2003, Science.
[61] V. Golubkov,et al. Anti-Angiogenic Activity of Contortrostatin, a Disintegrin from Agkistrodon Contortrix Contortrix Snake Venom , 2004, Angiogenesis.
[62] S. Mousa,et al. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. , 2000, The American journal of pathology.
[63] L. Liotta,et al. Biochemical interactions of tumor cells with the basement membrane. , 1986, Annual review of biochemistry.
[64] Y. Barenholz,et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.
[65] K. O'Byrne,et al. A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer , 2002, British Journal of Cancer.
[66] F. Muggia,et al. Liposomal encapsulated anthracyclines: new therapeutic horizons , 2001, Current oncology reports.
[67] J. Folkman. Tumor angiogenesis. , 1985, Advances in cancer research.
[68] D. Cheresh,et al. Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.
[69] L J Liang,et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] F. Markland,et al. Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits angiogenesis , 2004, Angiogenesis.
[71] R. Jain,et al. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. , 1994, Cancer research.
[72] S. Albelda,et al. Platelet endothelial cell adhesion molecule, PECAM‐1, modulates cell migration , 1992, Journal of cellular physiology.
[73] R. Perez-soler,et al. Liposomes as carriers of different new lipophilic antitumour drugs: a preliminary report. , 1994, Journal of microencapsulation.
[74] J. Folkman,et al. Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.
[75] S. Pileri,et al. Antigen retrieval techniques in immunohistochemistry: comparison of different methods , 1997, The Journal of pathology.
[76] Thomas Boehm,et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.
[77] Giampietro Gasparini,et al. Erratum: “Evaluating the Potential Usefulness of New Prognostic and Predictive Indicators in Node-Negative Breast Cancer Patients,” , 1993 .
[78] R. Jain,et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[79] G. Davis,et al. RGD-Dependent Vacuolation and Lumen Formation Observed during Endothelial Cell Morphogenesis in Three-Dimensional Fibrin Matrices Involves the αvβ3 and α5β1 Integrins , 2000 .
[80] F. Markland,et al. Snake Venom Disintegrin: An Effective Inhibitor of Breast Cancer Growth and Dissemination , 1999 .
[81] D. Phillips,et al. PECAM-1 is required for transendothelial migration of leukocytes , 1993, The Journal of experimental medicine.